Test cemiplimab for HPV-positive throat cancer using tumor biomarkers
Treatments studied
Part of Cancer, Ear, nose & throat clinical trials.
This Phase 2 trial studies whether cemiplimab (with or without chemotherapy first) can improve treatment for HPV-positive oropharynx throat cancer. It also uses lab “biomarkers” to help guide which treatment you get next.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be diagnosed with HPV-positive head and neck squamous cell cancer in the throat (oropharynx).
- Tumor must be HPV16-positive, or you may start briefly based on p16 testing while final HPV type tests are pending.
- Have measurable cancer on scans and/or exam (not only microscopic cancer).
- No prior radiation or chemotherapy for head and neck cancer.
- No cancer that has spread to distant organs (no M1 disease).
- Be able to do treatment and procedures: age 18+, and normal-enough blood counts/liver/kidney function (lab thresholds required).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a “risk-adapted” treatment plan for HPV-related throat cancer, using an HPV DNA blood test to help decide how treatment is done. If your baseline blood test shows detectable HPV DNA, the study may help tailor therapy to your risk and potentially improve outcomes while limiting unnecessary treatment.
This Phase 1 trial tests how well cemiplimab (an immune treatment) can work when combined with chemotherapy and an additional immunotherapy for certain head and neck cancers. It may help shrink the cancer and improve outcomes, while also checking safety and dosing.
This trial compares two different immunotherapy approaches for people with HPV-positive oropharyngeal cancer who have completed initial treatment like surgery, radiation, or chemotherapy. The goal is to see which option works better to keep the cancer from coming back, and eligibility is determined by a special blood test that detects HPV DNA.
This Phase 1 trial tests cemiplimab (an immune system medicine) given with “induction” chemotherapy before the main treatment for locally advanced squamous cell head and neck cancer. It’s designed to see how well this treatment is tolerated and to learn about immune responses that may help future patients.
This trial tests whether a blood test measuring HPV DNA can help doctors decide the best treatment for HPV-positive throat cancer. The goal is to use this information to guide whether patients need immunotherapy (a drug called pembrolizumab) after their initial treatment.
This trial tests whether combining two targeted drugs (cemiplimab and cetuximab) before surgery can help people with recurrent mouth or throat cancer that has come back after initial treatment. It aims to see if this approach makes surgery more effective.
Hear when a new HPV-Related Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.